Announcing a new publication for Acta Materia Medica journal. Inhibition or degradation of the anti-apoptotic protein BCL-XL is a viable strategy for cancer treatment. Despite the recent development of PROTACs for degradation of BCL-XL, the choice of E3 ligase has been restricted to VHL and CRBN. The authors of this article report the development of MDM2-BCL-XL PROTACs […]